For first-line therapy in NSCLC-BM patients, the unadjusted median PFS (mPFS) of first-generation and third-generation EGFR-TKIs was 9.27 months and 13.77 months, respectively, with no significant difference (Table 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.